Onderzoek naar de kosten-effectiviteit van het stoppen van bloeddrukverlagers en/of cholesterolverlagers bij patiënten met een laag risico op hart- en vaatziekten in de huisartsenpraktijk.

Completed

Conditions: Hypertensie, hypercholesterolemie, hart- en vaatziekten.Hypertension, hypercholesterolemia, cardiovascular disease.

Registration Number: NL-OMON29344

Lead Sponsor: MC - Leids Universitair Medisch CentrumAfdeling Public Health en Eerstelijnsgeneeskunde

Brief Summary: /A

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 464

Inclusion Criteria

1. Men and women aged 40 to 70 years;

2. Prescription of antihypertensive medication and/or lipid-lowering drugs for hypertension and/or hypercholesterolemia during the last 12 months (using ATC codes: C02, C03, C07, C08, C09, C10).

Exclusion Criteria

1. Cardiovascular disease (ICPC codes: K74, K75, K76, K89, K90.03, K91, K92.01 and K99.01);

2. Use of platelet aggregation inhibitors (heparin excluded) (ATC code: B01AC);

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measure is the change in 10-year CVD risk according to the risk table from the guideline CVRM 2011.

Secondary Outcome Measures

Name	Time	Method
Secondary outcome measures are quality of life (EQ-5D + VAS), health care costs, (CVD related) mortality, cardiovascular events and side effects related to withdrawal of medication or use of medication. Other outcome measures are related to modifiable risk factors, such as smoking behaviour (smoking behaviour questionnaire), physical activity (SQUASH), alcohol consumption, eating habits (Standard nutrition questionnaire of Dutch common health services), systolic blood pressure (SBP), ratio of total cholesterol/HDL-cholesterol (TC/HDL ratio) in blood, Body Mass Index (body weight and height), and waist circumference.